JP2023106433A5 - - Google Patents

Download PDF

Info

Publication number
JP2023106433A5
JP2023106433A5 JP2023075458A JP2023075458A JP2023106433A5 JP 2023106433 A5 JP2023106433 A5 JP 2023106433A5 JP 2023075458 A JP2023075458 A JP 2023075458A JP 2023075458 A JP2023075458 A JP 2023075458A JP 2023106433 A5 JP2023106433 A5 JP 2023106433A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023075458A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023106433A (ja
Filing date
Publication date
Priority claimed from JP2020505208A external-priority patent/JP2020529410A/ja
Application filed filed Critical
Publication of JP2023106433A publication Critical patent/JP2023106433A/ja
Publication of JP2023106433A5 publication Critical patent/JP2023106433A5/ja
Priority to JP2025092507A priority Critical patent/JP2025131681A/ja
Pending legal-status Critical Current

Links

JP2023075458A 2017-07-31 2023-05-01 Nkg2d、cd16及びflt3と結合するタンパク質 Pending JP2023106433A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025092507A JP2025131681A (ja) 2017-07-31 2025-06-03 Nkg2d、cd16及びflt3と結合するタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539421P 2017-07-31 2017-07-31
US62/539,421 2017-07-31
JP2020505208A JP2020529410A (ja) 2017-07-31 2018-07-31 Nkg2d、cd16及びflt3と結合するタンパク質

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020505208A Division JP2020529410A (ja) 2017-07-31 2018-07-31 Nkg2d、cd16及びflt3と結合するタンパク質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025092507A Division JP2025131681A (ja) 2017-07-31 2025-06-03 Nkg2d、cd16及びflt3と結合するタンパク質

Publications (2)

Publication Number Publication Date
JP2023106433A JP2023106433A (ja) 2023-08-01
JP2023106433A5 true JP2023106433A5 (cg-RX-API-DMAC7.html) 2023-12-01

Family

ID=65233032

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020505208A Pending JP2020529410A (ja) 2017-07-31 2018-07-31 Nkg2d、cd16及びflt3と結合するタンパク質
JP2023075458A Pending JP2023106433A (ja) 2017-07-31 2023-05-01 Nkg2d、cd16及びflt3と結合するタンパク質
JP2025092507A Pending JP2025131681A (ja) 2017-07-31 2025-06-03 Nkg2d、cd16及びflt3と結合するタンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020505208A Pending JP2020529410A (ja) 2017-07-31 2018-07-31 Nkg2d、cd16及びflt3と結合するタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025092507A Pending JP2025131681A (ja) 2017-07-31 2025-06-03 Nkg2d、cd16及びflt3と結合するタンパク質

Country Status (15)

Country Link
US (1) US20200165344A1 (cg-RX-API-DMAC7.html)
EP (1) EP3661554A4 (cg-RX-API-DMAC7.html)
JP (3) JP2020529410A (cg-RX-API-DMAC7.html)
KR (2) KR20250051800A (cg-RX-API-DMAC7.html)
CN (1) CN111132698A (cg-RX-API-DMAC7.html)
AU (2) AU2018309712A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020001972A2 (cg-RX-API-DMAC7.html)
CA (1) CA3070986A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020001981A2 (cg-RX-API-DMAC7.html)
EA (1) EA202090387A1 (cg-RX-API-DMAC7.html)
IL (1) IL272374A (cg-RX-API-DMAC7.html)
MA (1) MA49769A (cg-RX-API-DMAC7.html)
MX (1) MX2020001257A (cg-RX-API-DMAC7.html)
SG (1) SG11202000632QA (cg-RX-API-DMAC7.html)
WO (1) WO2019028027A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
MA52206A (fr) 2018-03-27 2021-02-17 Xyphos Biosciences Inc Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EP3902836B1 (en) 2018-12-18 2026-03-25 Boehringer Ingelheim IO Canada Inc. Flt3 agonist antibodies and uses thereof
BR112022007128A2 (pt) * 2019-10-15 2022-07-05 Dragonfly Therapeutics Inc Ligação de proteínas nkg2d, cd16 e flt3
BR112022016550A2 (pt) * 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
JP2024524378A (ja) * 2021-06-29 2024-07-05 山▲東▼先声生物制▲薬▼有限公司 Cd16抗体及びその応用
WO2026052582A1 (en) 2024-09-04 2026-03-12 Red Ridge Bio Ag Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077483A1 (en) * 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
ES2573642T3 (es) * 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
EP4310191A3 (en) * 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
EP4050026A1 (en) * 2014-04-01 2022-08-31 Adimab, LLC Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells

Similar Documents

Publication Publication Date Title
JP2023052214A5 (cg-RX-API-DMAC7.html)
Hosseini et al. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials
JP2021098732A5 (cg-RX-API-DMAC7.html)
JP2020507328A5 (cg-RX-API-DMAC7.html)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2020529410A5 (cg-RX-API-DMAC7.html)
JP2022551969A5 (cg-RX-API-DMAC7.html)
JP2020510646A5 (cg-RX-API-DMAC7.html)
JP2021534096A5 (cg-RX-API-DMAC7.html)
JP2023526774A5 (cg-RX-API-DMAC7.html)
JP2021533159A5 (cg-RX-API-DMAC7.html)
JP2020508997A5 (cg-RX-API-DMAC7.html)
JP2021523140A5 (cg-RX-API-DMAC7.html)
JP2022061993A5 (cg-RX-API-DMAC7.html)
JP2021533169A5 (cg-RX-API-DMAC7.html)
JP2020521448A5 (cg-RX-API-DMAC7.html)
JP2020522474A5 (cg-RX-API-DMAC7.html)
JP2021035388A5 (ja) Caix、ano1、メソテリン、trop2またはクローディン−18.2を標的にする多重特異性結合タンパク質
JP2020507577A5 (cg-RX-API-DMAC7.html)
JP2020533311A5 (ja) NKG2D、CD16およびNectin4に結合するタンパク質
JP2021512630A5 (cg-RX-API-DMAC7.html)
FI3749346T3 (fi) Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
JP2023123726A5 (cg-RX-API-DMAC7.html)
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
JP2019536430A5 (cg-RX-API-DMAC7.html)